白蛋白结合型紫杉醇治疗胰腺癌的研究进展  

Progression of Nab-paclitaxel for pancreatic carcinoma

作　　者：梅魁敏[1] 刘秀峰[1] 秦叔逵[1] 

机构地区：[1]解放军八一医院全军肿瘤中心肿瘤内科,南京210002

出　　处：《临床肿瘤学杂志》2014年第7期649-653,共5页Chinese Clinical Oncology

摘　　要：胰腺癌是消化系统常见的高度恶性肿瘤,起病隐匿、进展迅速、病程极短,预后不良。化疗是晚期胰腺癌患者不可或缺的重要治疗手段。多年来,吉西他滨是其唯一的金标准药物,但疗效有限。白蛋白结合型紫杉醇以其独特的剂型优势,治疗晚期胰腺癌取得了突破性进展,已经成为新的优选药物。Pancreatic carcinoma（ PC） is one of the most detrimental common digestive malignancies, which is characterized by hidden onset, rapid progression and short course. Chemotherapy is an indispensable treatment approaches for patients with advanced PC. Gemcitabine act as a gold standard drug, but its effect is limited. A new drug, that is Nab-paclitaxel with its unique formulation advantage, has made breakthrough progress in the treatment of advanced PC and has become the new standard chemotherapy drugs for advanced pancreatic carcinoma.

关 键 词：白蛋白结合型紫杉醇 胰腺癌 化学治疗 

分 类 号：R735.9[医药卫生—肿瘤]